Our results suggest that a simplified two-dimensional model can capture the extent to which the isolated adrenergic signaling pathway mediates both the potentially harmful effects of GRK2 in heart failure and the therapeutic benefits of its downregulation by pharmaceutical agents. Here, GRK2 is linked to heart failure.